Characterizing the cross-sectional approach to investigate the prevalence of tissue BRCA1/2 mutations in newly diagnosed advanced ovarian cancer patients

Trial Identifier: D0817R00018
Sponsor: AstraZeneca
NCTID:: NCT04222465
Start Date: March 2020
Primary Completion Date: November 2020
Study Completion Date: November 2020
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Ehime Matsuyama, Ehime, Japan
Japan, Ehime Toon, Ehime, Japan
Japan, Fukui Yoshida, Fukui, Japan
Japan, Fukuoka Kitakyushu, Fukuoka, Japan
Japan, Fukushima Fukushima, Japan
Japan, Gifu Gifu, Japan
Japan, Hokkaido Sapporo, Hokkaido, Japan
Japan, Hyogo Amagasaki, Hyogo, Japan
Japan, Hyogo Kobe, Hyogo, Japan
Japan, Ibaraki Tsukuba, Ibaraki, Japan
Japan, Kumamoto Kumamoto, Japan
Japan, Miyagi Sendai, Miyagi, Japan
Japan, Nara Kashihara, Nara, Japan
Japan, Niigata Niigata, Japan
Japan, Okayama Okayama, Japan
Japan, Shimane Izumo, Shimane, Japan
Japan, Shizuoka Mishima, Shizuoka, Japan
Japan, Tokyo Bunkyo, Tokyo, Japan
Japan, Tokyo Minato, Tokyo, Japan
Japan, Tokyo Musashino, Tokyo, Japan
Japan, Tokyo shinjuku, Tokyo, Japan
Japan, Yamagata Yamagata, Japan